<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7114316/results/search/drug/results.xml">
  <result pre="NSC343256 showed better EC50 values than the broad-spectrum antiviral drug" exact="ribavirin" post="and the protease inhibitor lopinavir, under all the test"/>
  <result pre="cultured in 5 mL of LB broth containing 100 μg/mL" exact="ampicillin" post="overnight at 37 °C. The correct constructs were subsequently"/>
  <result pre="CID5372747 336.20 ± 0.13 &amp;gt;100 N/A &amp;gt;200 N/A &amp;gt;200 N/A" exact="Ribavirin" post="CID37542 &amp;gt;500 48.87 ± 1.77 25.68 73.98 ± 0.18"/>
  <result pre="reference inhibitors, ribavirin, and lopinavir, were included in our experiments." exact="Ribavirin" post="is a synthetic nucleoside and a ribosyl purine analog"/>
  <result pre="purine analog with antiviral activity. The mechanism of action of" exact="ribavirin" post="is still unclear and highly variable among patients (Cameron"/>
  <result pre="hepatitis C virus (Dixit and Perelson, 2006). The activity of" exact="ribavirin" post="is enhanced by using its combination with interferons or"/>
  <result pre="drugs that synergistically inhibit the viruses, rather than treatment with" exact="ribavirin" post="alone, as reported for the MERS-CoV and SARS-CoV regimens"/>
  <result pre="SARS-CoV regimens (Falzarano et al., 2013; Omrani et al., 2014)." exact="Ribavirin" post="in combination with lopinavir/ritonavir and steroids showed a slight"/>
  <result pre="in several studies. In our pre- and post-viral entry experiments," exact="ribavirin" post="showed less antiviral effect on FIPV, compared to compounds"/>
  <result pre="of HIV protease, has been commonly used in combination with" exact="ritonavir" post="for treatment of HIV. The booted forms of lopinavir"/>
  <result pre="with ritonavir for treatment of HIV. The booted forms of" exact="lopinavir" post="and ritonavir have exhibited antiviral activities in some clinical"/>
  <result pre="for treatment of HIV. The booted forms of lopinavir and" exact="ritonavir" post="have exhibited antiviral activities in some clinical cases of"/>
  <result pre="al., 2004; Chan et al., 2003). It was expected that" exact="lopinavir" post="could possibly inhibit 3CLpro activity. However, lopinavir and its"/>
  <result pre="was expected that lopinavir could possibly inhibit 3CLpro activity. However," exact="lopinavir" post="and its derivatives partially inhibited the 3CLpro of SARS-CoV,"/>
  <result pre="~25 μM, respectively (Wu et al., 2004). We observed that" exact="lopinavir" post="effectively inhibited FIPV during the stage of viral entry"/>
  <result pre="viral entry (EC50 = 5.38–31.70 μM). It is possible that" exact="lopinavir" post="may have higher inhibitory activity toward other proteases when"/>
  <result pre="other host proteases such as furin protease, the action of" exact="lopinavir" post="might involve the blocking of furin-mediated cleavage during viral"/>
  <result pre="cleavage during viral entry. Therefore, the mechanism of action of" exact="lopinavir" post="on FIPV requires further investigation. The selectivity index, defined"/>
  <result pre="Biol.1263201524325025618350 DixitN.M.PerelsonA.S.The metabolism, pharmacokinetics and mechanisms of antiviral activity of" exact="ribavirin" post="against hepatitis C virusCell. Mol. Life Sci.63200683284216501888 FalzaranoD.de WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.BriningD.BushmakerT.MartellaroC.BaselerL.BeneckeA.G.KatzeM.G.MunsterV.J.FeldmannH.Treatment"/>
  <result pre="C virusCell. Mol. Life Sci.63200683284216501888 FalzaranoD.de WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.BriningD.BushmakerT.MartellaroC.BaselerL.BeneckeA.G.KatzeM.G.MunsterV.J.FeldmannH.Treatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV–infected rhesus macaquesNat. Med.192013131324013700 HerreweghA.A.P.M.De GrootR.J.CepicaA.EgberinkH.F.HorzinekM.C.RottierP.J.M.Detection"/>
  <result pre="compoundsAntivir. Res.682005364216115693 LipinskiC.A.Lead- and drug-like compounds: the rule-of-five revolutionDrug Discov." exact="Today" post="Technol.1200433734124981612 Lohézic-Le DévéhatF.TomasiS.ElixJ.A.RouaudI.UriacP.RennesD.Lohezic-Le DevehatF.TomasiS.ElixJ.A.BernardA.RouaudI.UriacP.BoustieJ.Stictic acid derivatives from the lichen"/>
 </snippets>
</snippetsTree>
